Last reviewed · How we verify
Fluarix and adjuvanted influenza vaccine
Fluarix and adjuvanted influenza vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Prevention of influenza disease caused by influenza A and B viruses in people 6 months of age and older..
Fluarix and adjuvanted influenza vaccine works by stimulating the body's immune system to produce antibodies against the influenza virus.
Fluarix and adjuvanted influenza vaccine works by stimulating the body's immune system to produce antibodies against the influenza virus. Used for Prevention of influenza disease caused by influenza A and B viruses in people 6 months of age and older..
At a glance
| Generic name | Fluarix and adjuvanted influenza vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This vaccine contains inactivated influenza virus antigens and an adjuvant to enhance the immune response. The adjuvant helps to increase the production of antibodies against the virus, providing protection against influenza infection.
Approved indications
- Prevention of influenza disease caused by influenza A and B viruses in people 6 months of age and older.
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines (NA)
- Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues. (EARLY_PHASE1)
- Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix and adjuvanted influenza vaccine CI brief — competitive landscape report
- Fluarix and adjuvanted influenza vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Fluarix and adjuvanted influenza vaccine
What is Fluarix and adjuvanted influenza vaccine?
How does Fluarix and adjuvanted influenza vaccine work?
What is Fluarix and adjuvanted influenza vaccine used for?
Who makes Fluarix and adjuvanted influenza vaccine?
What development phase is Fluarix and adjuvanted influenza vaccine in?
What are the side effects of Fluarix and adjuvanted influenza vaccine?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of influenza disease caused by influenza A and B viruses in people 6 months of age and older.
- Compare: Fluarix and adjuvanted influenza vaccine vs similar drugs
- Pricing: Fluarix and adjuvanted influenza vaccine cost, discount & access